AKT1 and colorectal cancer: For example, PI3Kα-specific inhibitors like BYL719 (alpelisib) have been shown to affect nuclear PtdIns(3,4,5)P3 signaling, thereby modulating nuclear AKT activation in colorectal cancer (Palmieri et al., 2023).